L-165,041

L-165,041 is a synthetic compound that acts as a selective agonist for the peroxisome proliferator-activated receptor beta/delta (PPARβ/δ). This compound has been extensively studied for its potential therapeutic applications in metabolic disorders, cardiovascular diseases, and inflammatory conditions.

Chemical Structure and Properties

L-165,041 is a member of the class of compounds known as phenylpropanoids. Its chemical structure is characterized by a phenyl group attached to a propanoic acid moiety. The molecular formula of L-165,041 is C₁₉H₁₈O₃, and it has a molecular weight of 294.35 g/mol.

Mechanism of Action

L-165,041 functions as a selective agonist for PPARβ/δ, a nuclear receptor that regulates the expression of genes involved in lipid metabolism, energy homeostasis, and inflammation. Upon binding to PPARβ/δ, L-165,041 induces a conformational change in the receptor, facilitating the recruitment of coactivators and the transcription of target genes.

Pharmacological Effects

Studies have shown that L-165,041 can modulate lipid metabolism by increasing the oxidation of fatty acids and enhancing insulin sensitivity. This makes it a potential candidate for the treatment of type 2 diabetes and obesity. Additionally, L-165,041 has been observed to exert anti-inflammatory effects, which may be beneficial in conditions such as atherosclerosis and rheumatoid arthritis.

Research and Clinical Applications

Research on L-165,041 has primarily focused on its role in metabolic and cardiovascular diseases. Preclinical studies in animal models have demonstrated its ability to improve lipid profiles, reduce body weight, and decrease inflammation. However, clinical trials in humans are necessary to fully establish its efficacy and safety profile.

Safety and Toxicity

The safety profile of L-165,041 is still under investigation. While preclinical studies have not reported significant adverse effects, the long-term safety of this compound in humans remains to be determined. Potential side effects may include alterations in liver function and lipid levels.

Also see

• Peroxisome proliferator-activated receptor
• PPAR agonists
• Metabolic syndrome
• Lipid metabolism